Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Winter;19(1):355-365.
doi: 10.22037/ijpr.2020.112646.13878.

A Preliminary Study of NER and MMR Pathways Involved in Chemotherapy Response in Bladder Transitional Cell Carcinoma: Impact on progression-free survival

Vahideh Montazeri  1 , Mohammad Hossein Ghahremani  1 , Hamed Montazeri  2 , Mandana Hasanzad  3 , D Majid Safavi  4 , Mohsen Ayati  5 , Mohammad Chehrazi  6 , Baharak Arefi Moghaddam  7 , Seyed Nasser Ostad  8
Affiliations

A Preliminary Study of NER and MMR Pathways Involved in Chemotherapy Response in Bladder Transitional Cell Carcinoma: Impact on progression-free survival

Vahideh Montazeri et al. Iran J Pharm Res. 2020 Winter.

Abstract

One of the main genotoxic drugs used in bladder cancer chemotherapy is cisplatin. While it is applied in most types of cancers, resistance to cisplatin is wildly common. In order to overcome drug resistance, it is necessary to determine a predictive marker. This study was conducted to provide basic data for selecting and designing a gene profile for further cohort and RCT studies in the future to improve response to treatment in bladder cancer. The expression levels of ERCC1, MLH1, MSH2, and CTR1 mRNA were determined in the tumor tissue using real-time q-PCR. Progression-free survival (PFS) was analyzed in term of the level of genes expression. The results revealed that the level of ERCC1 mRNA expression was higher in the recurrence (R) group compared to the no recurrence (NR) group. Moreover, the PFS time was increased in the patients with an ERCC1 expression level of below 1.57. The level of MLH1 and MSH2 mRNA expression was lower in the R group compared to the NR group; therefore, PFS time was increased in the patients with MLH1 and MSH2 gene expression levels above the cutoff point. While the level of CTR1 mRNA expression was higher in the R group versus the NR group, the PFS time was longer in the patients with CTR1 expression levels of below 1.265 compared to the patients with high levels of CTR1 expression. It can be concluded that the level of ERCC1, MLH1, MSH2, and CTR1 mRNA expression may be associated with PFS time as possible therapeutic targets for decreasing cisplatin resistance.

Keywords: Carcinoma; Cisplatin; Copper transporter 1 protein; Human; Progression-free survival; Transitional cell.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patient's papulation
Figure 2
Figure 2
Expression levels of MLH1, ERCC1, MSH2, and CTR1 in NR and R groups (mean ± SD)
Figure 3.
Figure 3.
Evaluation of recurrence in patients with gene expression levels below and above the cutoff point. (A and B) Patients with MLH1, MSH2 mRNA expression levels above the cutoff point had longer the PFS compared to other patients. (C and D), Patients with ERCC1 and CTR1 mRNA expression levels above the cutoff point had shorter the PFS compared to other patients
See this image and copyright information in PMC

References

    1. Cumberbatch MGK, Jubber I, Black PC, Esperto F, Figueroa JD, Kamat AM, Kiemeney L, Lotan Y, Pang K, Silverman DT. Epidemiology of bladder cancer: A systematic review and contemporary update of risk factors in 2018. Eur. Urol. . 2018;74:784–95. - PubMed
    1. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: A global overview and recent trends. Eur. Urol. . 2017;71:96–108. - PubMed
    1. Knowles MA, Hurst CD. Molecular biology of bladder cancer: New insights into pathogenesis and clinical diversity. Nat. Rev. Cancer . 2015;15:25–41. - PubMed
    1. Nezos A, Pissimisis N, Lembessis P, Sourla A, Dimopoulos P, Dimopoulos T, Tzelepis K, Koutsilieris M. Detection of circulating tumor cells in bladder cancer patients. Cancer Treat. Rev. . 2009;35:272–9. - PubMed
    1. Wong MC, Fung FD, Leung C, Cheung WW, Goggins WB, Ng C. The global epidemiology of bladder cancer: A joinpoint regression analysis of its incidence and mortality trends and projection. Sci. Rep. . 2018;8:1129. - PMC - PubMed

LinkOut - more resources